TXG Stock Recent News

Researchers used Chromium Single Cell products and Xenium In Situ to profile how gene expression is spatially regulated during secondary palate formation PLEASANTON, Calif., June 27, 2024 /PRNewswire/ -- 10x Genomics, Inc.  (Nasdaq: TXG), a leader in single cell and spatial biology, announced today that its Xenium In Situ platform was used in a study published in the Journal of Dental Research, offering novel insights into cellular mechanisms regulating the formation of the secondary palate.

10x Genomics has experienced a significant decline in share price, currently trading around $20 per share, with no bullish indicators for a potential reversal. Recent performance shows growth in total revenue to $141M, but with a decrease in consumables revenue and a rise in operating costs, leading to an operating loss. Factors contributing to the decline in TXG include economic influences, fading growth prospects, supply chain issues, legal battles with NanoString Technologies, and a lack of retail investor interest.

New 5,000-plex gene panel increases plex by an order of magnitude and delivers industry-leading speed and throughput PLEASANTON, Calif. , June 20, 2024 /PRNewswire/ -- 10x Genomics, Inc. (Nasdaq: TXG), a leader in single cell and spatial biology, announced today that it has started shipping its new Xenium Prime 5K Pan-Tissue and Pathways panel.

PHILADELPHIA, PA / ACCESSWIRE / June 11, 2024 / Kaskela Law LLC announces that it is investigating 10x Genomics, Inc. (NASDAQ:TXG) on behalf of the company's stockholders. The investigation seeks to determine whether 10x Genomics and/or the company's officers and directors violated the securities laws or breached their fiduciary duties to the company's investors in connection with recent corporate actions.

Pipeline of high-quality targets systematically prioritized to unlock the full potential of Morelos (All amounts expressed in U.S. dollars unless otherwise stated) Toronto, Ontario--(Newsfile Corp. - June 10, 2024) - Torex Gold Resources Inc. (the "Company" or "Torex") (TSX: TXG) is pleased to provide detail on a multi-year exploration strategy for its highly prospective Morelos Property ("Morelos"), designed to generate incremental additions to mineral resources in the near term, generate at least one new discovery in the mid-term, and extend the mine life at Morelos in order to deliver stable production and cash flow well beyond 2033. Jody Kuzenko, President & CEO of Torex, stated: "Since 2021, our exploration strategy has been focused on shoring up the near-term production profile and identifying future sources of feed to fill the mill beyond 2027.

New Xenium Prime 5K Pan-Tissue and Pathways panel increases plex by an order of magnitude and delivers industry-leading speed and throughput PLEASANTON, Calif. , May 29, 2024 /PRNewswire/ --  10x Genomics, Inc. (Nasdaq: TXG), a leader in single cell and spatial biology, announced today the launch of its Xenium Prime 5K Pan-Tissue and Pathways panel.

Report shines a spotlight on continued excellence in ESG performance and disclosure (All amounts expressed in U.S. dollars unless otherwise stated) Toronto, Ontario--(Newsfile Corp. - May 21, 2024) - Torex Gold Resources Inc. (the "Company" or "Torex") (TSX: TXG) today released its 2023 Responsible Gold Mining Report (the "Report") titled At the Heart of Who we Are, the Company's ninth annual disclosure of its Environmental, Social and Governance ("ESG") performance. The Report can be found on the Company's website at www.torexgold.com.

Review 10x Genomics' (TXG) international revenue performance and how it affects the predictions of financial analysts on Wall Street and the future prospects for the stock.

PLEASANTON, Calif. , May 2, 2024 /PRNewswire/ -- 10x Genomics, Inc. (Nasdaq: TXG), a leader in single cell and spatial biology, today announced that members of its management team will participate in a fireside chat at the BofA Securities 2024 Healthcare Conference on Tuesday, May 14, at 4:20 p.m.

10x Genomics, Inc. (NASDAQ:TXG ) Q1 2024 Earnings Conference Call April 30, 2024 4:30 PM ET Company Participants Cassie Corneau - Director of Investor Relations & Strategic Finance Serge Saxonov - Chief Executive Officer & Co-Founder Justin McAnear - Chief Financial Officer Conference Call Participants Mason Carrico - Stephens, Inc. Patrick Donnelly - Citigroup Daniel Arias - Stifel Financial Doug Schenkel - Wolfe Research Dan Brennan - TD Cowen Matt Larew - William Blair Matthew Sykes - Goldman Sachs Subbu Nambi - Guggenheim Partners Michael Ryskin - Bank of America Tejas Savant - Morgan Stanley Luke Sergott - Barclays Kyle Mikson - Canaccord Genuity Operator Good day everyone and welcome to the 10x Genomics First Quarter 2024 Earnings Call. Today's call is being recorded.